Published in Anti-Infectives Week, September 20th, 2004
"BAL9141 is a novel cephalosporin with a broad spectrum of activity, including activity against methicillin-resistant staphylococci. This multicenter study was performed to establish quality control (QC) guidelines for susceptibility testing of BAL9141 in phase 3 clinical trials and after U.S. Food and Drug Administration approval," investigators in the United States report.
"The proposed 3 or 4 log2 dilution MIC ranges encompass 97.8 to 100.0% of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Anti-Infectives Week
Source: Anti-Infectives Week (2004-09-20)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.